Table 2 Key determinants of prognosis of COVID-19 associated neurological disorders. Bold text indicates subsection headings or statistical significance. *p < 0.05 (SD - standard deviation, OR - odds ratio, CI - confidence interval)
From: Neurological disorders associated with COVID-19 in Sri Lanka
Determinant | Group A: Partial/complete recovery (n = 144) | Group B: No recovery/death (n = 24) | Significance |
|---|---|---|---|
Demographic characteristic / comorbidity | |||
Age (Mean years) | 48.3 (SD 23.8) | 56.5 (SD 20.8) | p = 0.115 |
Gender (% male) | 53.5% (77) | 58.3% (14) | p = 0.825 |
Vaccinated | 48.6% (70) | 37.5% (9) | p = 0.380 |
Time from last vaccine to neurological onset (mean days) | 43.3 (SD 45.5) (n = 57) | 18.8 (SD 18.2) (n = 7) | p = 0.166 |
Symptomatic COVID-19 infection | 70.6% (96/136) | 75.0% (18/24) | p = 0.808 |
Supplemental oxygen required | 21.5% (31) | 45.8% (11) | p = 0.020* OR = 12.93 (CI = 1.05–160.17; p = 0.046) |
Diabetes | 21.5% (31) | 41.7% (10) | p = 0.042* |
Hypertension | 27.1% (39) | 45.8 (11) | p = 0.090 |
Ischaemic heart disease | 7.6% (11) | 12.5% (3) | p = 0.426 |
Neurological disorder | |||
Ischaemic stroke | 86.3% (44/51) | 13.7% (7/51) | p = 1.000 |
Haemorrhagic stroke | 60.0% (3/5) | 40.0% (2/5) | p = 0.149 |
Encephalitis | 92.9% (13/14) | 7.1% (1/14) | p = 0.695 |
Encephalopathy | 77.3% (17/22) | 22.7% (5/22) | p = 0.322 |
Cerebral venous thrombosis | 80.0% (4/5) | 20.0% (1/5) | p = 0.542 |
Epilepsy | 100.0 (7/7) | 0.0% (0/7) | |
Guillain–Barre syndrome | 93.8% (15/16) | 6.3% (1/16) | p = 0.474 |
Myelitis | 100.0% (8/8) | 0.0% (0/8) | |